Nirmatrelvir/ritonavir (Paxlovid) reduces hospitalization, mortality in patients 65+ with COVID-19; effect on younger patients unclear
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2024 Unbound Medicine, Inc. All rights reserved